7zfc › Citations

Potent cross-reactive antibodies following Omicron breakthrough in vaccinees.
<div class='caption-title'>The sub-lineages of Omicron and neutralization of BA.1 and BA.2 by vaccine and Omicron serum</div>
<div class='caption-title'>mAb production and neutralization curves for BA.1, BA.1.1 and BA.2</div>
Nutalai R, Zhou D, Tuekprakhon A, Ginn HM, Supasa P, Liu C, Huo J, Mentzer AJ, Duyvesteyn HME, Dijokaite-Guraliuc A, Skelly D, Ritter TG, Amini A, Bibi S, Adele S, Johnson SA, Constantinides B, Webster H, Temperton N, Klenerman P, Barnes E, Dunachie SJ, Crook D, Pollard AJ, Lambe T, Goulder P, Paterson NG, Williams MA, Hall DR, Mongkolsapaya J, Fry EE, Dejnirattisai W, Ren J, Stuart DI, Screaton GR
OpenAccess logo Cell 185 2116-2131.e18 (2022)
Related entries: 7zf3, 7zf4, 7zf5, 7zf6, 7zf7, 7zf8, 7zf9, 7zfa, 7zfb, 7zfd, 7zfe, 7zff, 7zr7, 7zr8, 7zr9, 7zrc

Cited: 85 times
EuropePMC logo PMID: 35662412

Abstract

Highly transmissible Omicron variants of SARS-CoV-2 currently dominate globally. Here, we compare neutralization of Omicron BA.1, BA.1.1, and BA.2. BA.2 RBD has slightly higher ACE2 affinity than BA.1 and slightly reduced neutralization by vaccine serum, possibly associated with its increased transmissibility. Neutralization differences between sub-lineages for mAbs (including therapeutics) mostly arise from variation in residues bordering the ACE2 binding site; however, more distant mutations S371F (BA.2) and R346K (BA.1.1) markedly reduce neutralization by therapeutic antibody Vir-S309. In-depth structure-and-function analyses of 27 potent RBD-binding mAbs isolated from vaccinated volunteers following breakthrough Omicron-BA.1 infection reveals that they are focused in two main clusters within the RBD, with potent right-shoulder antibodies showing increased prevalence. Selection and somatic maturation have optimized antibody potency in less-mutated epitopes and recovered potency in highly mutated epitopes. All 27 mAbs potently neutralize early pandemic strains, and many show broad reactivity with variants of concern.

Articles - 7zfc mentioned but not cited (2)

  1. Potent cross-reactive antibodies following Omicron breakthrough in vaccinees. Nutalai R, Zhou D, Tuekprakhon A, Ginn HM, Supasa P, Liu C, Huo J, Mentzer AJ, Duyvesteyn HME, Dijokaite-Guraliuc A, Skelly D, Ritter TG, Amini A, Bibi S, Adele S, Johnson SA, Constantinides B, Webster H, Temperton N, Klenerman P, Barnes E, Dunachie SJ, Crook D, Pollard AJ, Lambe T, Goulder P, OPTIC consortium, ISARIC4C consortium, Paterson NG, Williams MA, Hall DR, Mongkolsapaya J, Fry EE, Dejnirattisai W, Ren J, Stuart DI, Screaton GR. Cell 185 2116-2131.e18 (2022)
  2. A delicate balance between antibody evasion and ACE2 affinity for Omicron BA.2.75. Huo J, Dijokaite-Guraliuc A, Liu C, Zhou D, Ginn HM, Das R, Supasa P, Selvaraj M, Nutalai R, Tuekprakhon A, Duyvesteyn HME, Mentzer AJ, Skelly D, Ritter TG, Amini A, Bibi S, Adele S, Johnson SA, Paterson NG, Williams MA, Hall DR, Plowright M, Newman TAH, Hornsby H, de Silva TI, Temperton N, Klenerman P, Barnes E, Dunachie SJ, Pollard AJ, Lambe T, Goulder P, OPTIC consortium, ISARIC4C consortium, Fry EE, Mongkolsapaya J, Ren J, Stuart DI, Screaton GR. Cell Rep 42 111903 (2023)


Reviews citing this publication (9)

  1. The evolution of SARS-CoV-2. Markov PV, Ghafari M, Beer M, Lythgoe K, Simmonds P, Stilianakis NI, Katzourakis A. Nat Rev Microbiol 21 361-379 (2023)
  2. The outbreak of SARS-CoV-2 Omicron lineages, immune escape, and vaccine effectivity. Zhou Y, Zhi H, Teng Y. J Med Virol 95 e28138 (2023)
  3. Convergent Evolution in SARS-CoV-2 Spike Creates a Variant Soup from Which New COVID-19 Waves Emerge. Focosi D, Quiroga R, McConnell S, Johnson MC, Casadevall A. Int J Mol Sci 24 2264 (2023)
  4. From Alpha to Omicron: How Different Variants of Concern of the SARS-Coronavirus-2 Impacted the World. Andre M, Lau LS, Pokharel MD, Ramelow J, Owens F, Souchak J, Akkaoui J, Ales E, Brown H, Shil R, Nazaire V, Manevski M, Paul NP, Esteban-Lopez M, Ceyhan Y, El-Hage N. Biology (Basel) 12 1267 (2023)
  5. The Epidemiological Features of the SARS-CoV-2 Omicron Subvariant BA.5 and Its Evasion of the Neutralizing Activity of Vaccination and Prior Infection. Tian D, Nie W, Sun Y, Ye Q. Vaccines (Basel) 10 1699 (2022)
  6. Broadly neutralizing antibodies against COVID-19. Zhou D, Ren J, Fry EE, Stuart DI. Curr Opin Virol 61 101332 (2023)
  7. Deep learning-based molecular dynamics simulation for structure-based drug design against SARS-CoV-2. Sun Y, Jiao Y, Shi C, Zhang Y. Comput Struct Biotechnol J 20 5014-5027 (2022)
  8. Neutralizing and enhancing antibodies against SARS-CoV-2. Liu Y, Arase H. Inflamm Regen 42 58 (2022)
  9. Respiratory viruses interacting with cells: the importance of electrostatics. Lauster D, Osterrieder K, Haag R, Ballauff M, Herrmann A. Front Microbiol 14 1169547 (2023)

Articles citing this publication (74)



Quick links